Overview

A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

Status:
Terminated
Trial end date:
2018-06-13
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics of different dose roflumilast in China COPD patient.
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd